[1]陈建新,姚丽华,王惠玲,等.谷氨酸转运体EAAT2在抑郁症发病及治疗中的作用[J].中国药理学通报,2016,(07):894-897.[doi:10.3969/j.issn.1001-1978.2016.07.002]
 CHEN Jian-xin,YAO Li-hua,WANG Hui-ling,et al.Roles of glutamate transporter EAAT2 in occurrence and treatment of depression[J].Chinese Pharmacological Bulletin,2016,(07):894-897.[doi:10.3969/j.issn.1001-1978.2016.07.002]
点击复制

谷氨酸转运体EAAT2在抑郁症发病及治疗中的作用()
分享到:

《中国药理学通报》[ISSN:/CN:]

卷:
期数:
2016年07期
页码:
894-897
栏目:
讲座与综述
出版日期:
2016-07-15

文章信息/Info

Title:
Roles of glutamate transporter EAAT2 in occurrence and treatment of depression
文章编号:
1001-1978(2016)07-0894-04
作者:
陈建新12姚丽华2王惠玲2刘忠纯2王晓萍2肖 玲2舒 畅2王高华2
1.湖北大学教育学院心理学系,湖北 武汉 430062;
2.武汉大学人民医院精神卫生中心,湖北 武汉 430060
Author(s):
CHEN Jian-xin12 YAO Li-hua2 WANG Hui-ling2 LIU Zhong-chun2 WANG Xiao-ping2 XIAO Ling2 SHU Chang2 WANG Gao-hua2
1.Dept of Psychology, Faculty of Education, Hubei University, Wuhan 430062, China;
2.Dept of Psychiatry, Renmin Hospital, Wuhan University, Wuhan 430060,China
关键词:
谷氨酸转运体EAAT2 抑郁 抗抑郁药 转运功能障碍 利鲁唑 头孢曲松
Keywords:
glutamate transporter EAAT2 depression antidepressant transport dysfunction riluzole ceftriaxone
分类号:
R-05;R749.420.2;R749.420.5;R977.4;R971.43
DOI:
10.3969/j.issn.1001-1978.2016.07.002
文献标志码:
A
摘要:
谷氨酸转运体EAAT2(啮齿类动物命名为GLT-1:谷氨酸转运体1)是海马和前额叶星形胶质细胞上一种非常重要的谷氨酸转运体,其承担了细胞外大部分谷氨酸的摄取和转运,由于谷氨酸转运体EAAT2的作用在于降低突触间隙过高的谷氨酸水平,避免过高浓度的谷氨酸对神经元和神经胶质细胞的兴奋毒性作用,使之逐渐成为近年来抑郁症研究的热点。该文主要就谷氨酸转运体EAAT2在抑郁症中可能的病理生理作用,以及其可能作为新一代抗抑郁药作用的靶点进行综述。
Abstract:
The glutamate transporter EAAT2(rodent nomenclature GLT-1: glutamate transporter 1), which is a predominantly astroglial glutamate transporter in the hippocampus and the prefrontal cortex, is responsible for the majority of extracellular glutamate uptake. The glutamate transporter EAAT2 can decrease the high levels of glutamate in the synaptic cleft, avoiding glutamatergic excitotoxicity to damage the glial cells and neurons. Currently, the transporter EAAT2 has become a research hotspot of depression. This article aims to summarize roles of glutamate transporter EAAT2 in the occurrence and treatment of depression.

参考文献/References:

[1] Tokita K, Yamaji T, Hashimoto K. Roles of glutamate signaling in preclinical and/or mechanistic models of depression[J]. Pharmacol Biochem Behav, 2012,100(4): 688-704.
[2] Banasr M, Duman R S. Regulation of neurogenesis and gliogenesis by stress and antidepressant treatment[J]. CNS Neurol Disord Drug Targets, 2007,6(5): 311-20,
[3] Rajkowska G, Miguel-Hidalgo J J. Gliogenesis and glial pathology in depression[J]. CNS Neurol Disord Drug Targets, 2007,6(3): 219-33.
[4] 张 兵, 李 扬.针对谷氨酸能系统的抗抑郁药物的研究进展[J].中国药理学通报, 2014,30(9):1197-200.
[4] Zhang B, Li Y. Research progress of the antidepressants targeting the glutamate receptors[J]. Chin Pharmacol Bull, 2015, 30(9): 1197-200.
[5] Choudary P V, Molnar M, Evans S J, Tomita H, et al. Altered cortical glutamatergic and GABAergic signal transmission with glial involvement in depression[J]. Proc Natl Acad Sci USA,2005,102(43): 15653-8.
[6] Bernard R, Kerman I A, Thompson R C, et al. Altered expression of glutamate signaling, growth factor, and glia genes in the locus coeruleus of patients with major depression[J]. Mol Psychiatry, 2011,16(6): 634-46.
[7] Miguel-Hidalgo J J, Waltzer R, Whittom A A,et al. Glial and glutamatergic markers in depression, alcoholism, and their comorbidity[J]. J Affect Disord, 2010,127(1-3): 230-40.
[8] Zink M, Vollmayr B, Gebicke-H¨arter P J, Henn F A. Reduced expression of glutamate transporters vGluT1, EAAT2 and EAAT4 in learned helpless rats, an animal model of depression[J]. Neuro Pharmacology, 2010,58(2): 465-73.
[9] Gourley S L, Espitia J W, Sanacora G, et al. Antidepressant like properties of oral riluzole and utility of incentive disengagement models of depression in mice[J]. Psychopharmacology(Berl), 2012,219(3): 805-14.
[10] Bradesi S, Golovatscka V, Ennes H S,et al. Role of astrocytes and altered regulation of spinal glutamatergic neurotransmission in stress-induced visceral hyperalgesia in rats[J]. Am J Physiol Gastrointest Liver Physiol, 2011,301(3): G580-9.
[11] 陈建新, 姚丽华, 王惠玲,等. 氟西汀对慢性应激大鼠前额叶谷氨酸转运体GLT-1 表达的影响[J].中国药理学通报, 2015,31(2): 256-60.
[11] Chen J X, Yao L H, Wang H L, et al. Effects of fluoxetine on changes of GLT-1 in rat prefrontal cortex after chronic unpredictable stress[J]. Chin Pharmacol Bull, 2015,31(2): 256-60.
[12] Chen J X, Yao L H, Xu B B, et al. Glutamate transporter 1-mediated antidepressant-like effect in a rat model of chronic unpredictable stress[J]. Huazhong Univ Sci Technol(Med Sci), 2014,34(6): 838-44.
[13] Reagan L P, Rosell D R, Wood G E, et al. Chronic restraint stress up-regulates GLT-1 mRNA and protein expression in the rat hippocampus: Reversal by tianeptine[J]. Proc Natl Acad Sci USA, 2004,101(7): 2179-84.
[14] Wood G E, Young L T, Reagan L P, et al. Stress-induced structural remodeling in hippocampus: Prevention by lithium treatment[J]. Proc Natl Acad Sci USA, 2004,101(11): 3973-8.
[15] Raudensky J, Yamamoto B K. Effects of chronic unpredictable stress and methamphetamine on hippocampal glutamate function[J]. Brain Res, 2007,1135(1): 129-35.
[16] Lee Y, Gaskins D, Anand A, et al. Glia mechanisms in mood regulation: a novel model of mood disorders[J]. Psychopharmacology, 2007,191(1): 55-65.
[17] Cui W P, Mizukami H, Yanagisawa M, et al. Glial dysfunction in the mouse habenula causes depressive-like Behaviors and Sleep Disturbance[J]. Journal Neurosci, 2014,34(49): 16273-85.
[18] Bechtholt-Gompf A J, Walther H V, Adams M A,et al. Blockade of astrocytic glutamate uptake in rats induces signs of anhedonia and impaired spatial memory[J]. Neuropsychopharmacology, 2010,35(10): 2049-59.
[19] John C S, Smith K L, Veer A V,et al. Blockade of astrocytic glutamate uptake in the prefrontal cortex induces anhedonia[J]. Neuropsychopharmacology, 2012,37(11): 2467-75.
[20] John C S, Sypek E I, Carlezon W A,et al. Blockade of the GLT-1 Transporter in the Central Nucleus of the Amygdala Induces both Anxiety and Depressive-Like Symptoms[J]. Neuropsychopharmacology, 2015,40(7): 1700-8.
[21] Verhave P S, Jongsma M J, Van Den Berg R M, et al. Neuroprotective effects of riluzole in early phase Parkinson's disease on clinically relevant parameters in the marmoset MPTP mode[J].Neuropharmacology, 2012,62(4): 1700-7.
[22] Yoshizumi M, Eisenach J C, Hayashida K. Riluzole and gabapentinoids activate glutamate transporters to facilitate glutamate-induced glutamate release from cultured astrocytes[J]. Eur J Pharmacol, 2012,677(1-3):87-92.
[23] Fumagalli E, Funicello M, Rauen T, et al. Riluzole enhances the activity of glutamate transporters GLAST, GLT1 and EAAC1[J]. Eur J Pharmacol, 2008,578(2-3): 171-6.
[24] Carbone M, Duty S, Rattray M. Riluzole elevates GLT-1 activity and levels in striatal astrocytes[J]. Neurochem Int,2012,60(1): 31-8.
[25] Liu A Y, Mathur R, Mei N, et al. Neuroprotective drug riluzole amplifies the heat shock factor 1(HSF1)-and glutamate transporter 1(GLT1)-dependent cytoprotective mechanisms for neuronal survival[J]. J Biol Chem, 2011,286(4): 2785-94.
[26] Pittenger C, Coric V, Banasr M, et al. Riluzole in the treatment of mood and anxiety disorders[J]. CNS Drugs, 2008,22(9): 761-86.
[27] Banasr M, Chowdhury G M, Terwilliger R, et al. Glial pathology in an animal model of depression: Reversal of stress-induced cellular, metabolic and behavioral deficits by the glutamate-modulating drug riluzole[J]. Mol Psychiatry, 2010,15(5): 501-11.
[28] Zarate Jr C A, Payne J L, Quiroz J, et al. An open-label trial of riluzole in patients with treatment-resistant major depression[J]. Am J Psychiatry, 2004,161(1): 171-4.
[29] Zarate Jr C A, Quiroz J A, Singh J B,et al. An open-label trial of the glutamate-modulating agent riluzole in combination with lithium for the treatment of bipolar depression[J]. Biol Psychiatry, 2005,57(4): 430-2.
[30] Sanacora G, Kendell S F, Levin Y, et al. Preliminary Evidence of Riluzole Efficacy Antidepressant-Treated Patients with Residual Depressive Symptoms[J]. Biol Psychiatry, 2007,61(6): 822-5.
[31] Pittenger C, Kelmendi B, Wasylink S, et al. Riluzole augmentation in treatment-refractory obsessive-compulsive disorder: A series of 13 cases, with long-term follow-up[J]. J Clin Psychopharmacol, 2008,28(3): 363-7.
[32] Rothstein J D, Patel S, Regan M R,et al. Beta-lactam antibiotics offer neuroprotection by increasing glutamate transporter expression[J]. Nature, 2005,433(7021): 73-7.
[33] Sari Y, Sakai M, Weedman J M,et al. Ceftriaxone, a beta-lactam antibiotic, reduces ethanol consumption in alcohol preferring rats[J]. Alcohol Alcohol, 2011,46(3): 239-46.
[34] Knackstedt L A, Melendez R I, Kalivas P W. Ceftriaxone restores glutamate homeostasis and prevents relapse to cocaine seeking[J]. Biol Psychiatry, 2010,67(1): 81-4.
[35] Mineur Y S, Picciotto M R, Sanacora G. Antidepressant-like effects of ceftriaxone in male C57BL/6J mice[J]. Biol Psychiatry, 2007,61(2): 250-2.
[36] 陈建新, 姚丽华, 王惠玲, 等. 头孢曲松对抑郁模型C57小鼠行为及海马谷氨酸转运体-1蛋白表达的影响[J]. 中华行为医学与脑科学杂志, 2015,24(5): 389-92.
[36] Chen J X, Yao L H, Wang H L,et al. Effects of ceftriaxone on depressive-like behavior and changes of hippocampal glutamate transporter-1 in depression model C57 mice[J]. Chin J Behav Med Brain Sci, 2015,24(5): 389-92.

相似文献/References:

[1]陈姣,楚世峰,李婧,等.FK506 binding protein 51参与糖皮质激素介导的抑郁样行为的发生[J].中国药理学通报,2014,(03):407.
 CHEN Jiao,CHU Shi-feng,LI Jing,et al.FK506 binding protein 51 is involved in the depression-likebehaviors induced by glucocorticoids[J].Chinese Pharmacological Bulletin,2014,(07):407.
[2]沈一维,律 峰,黎 平,等.氯胺酮联合氟西汀对抑郁大鼠前额叶nNOS及其配体CAPON表达的影响[J].中国药理学通报,2015,(04):487.
 SHEN Yi-wei,LYu Feng,LI Ping,et al.Effects of ketamine plus fluoxetine on nNOS and CAPON expression in the prefrontal lobe of mentally depressed rats[J].Chinese Pharmacological Bulletin,2015,(07):487.
[3]韦桂宁,楚世峰,苏 华,等.拟黑多刺蚁醇提物抗抑郁作用研究[J].中国药理学通报,2015,(09):1280.[doi:10.3969/j.issn.1001-1978.2015.09.020]
 WEI Gui-ning,CHU Shi-feng,SU Hua,et al.Antidepressive-like effect of alcoholic extract of Polyrhachis vicina Roger[J].Chinese Pharmacological Bulletin,2015,(07):1280.[doi:10.3969/j.issn.1001-1978.2015.09.020]
[4]徐亚运,葛金芳,陈飞虎.Nesfatin-1在抑郁症发病中的作用研究进展[J].中国药理学通报,2015,(08):1044.[doi:10.3969/j.issn.1001-1978.2015.08.003]
 XU Ya-yun,GE Jin-fang,CHEN Fei-hu.Advances in studies on role of Nesfatin-1 in depression[J].Chinese Pharmacological Bulletin,2015,(07):1044.[doi:10.3969/j.issn.1001-1978.2015.08.003]
[5]曹莉莎,张 芳,罗 文,等.抑郁大鼠海马组织的比较蛋白质组学研究[J].中国药理学通报,2016,(05):697.[doi:10.3969/j.issn.1001-1978.2016.05.020]
 CAO Li-sha,ZHANG Fang,LUO Wen,et al.Analysis of CUMS-induced differentially expressed proteins in rat hippocampus by ITRAQ[J].Chinese Pharmacological Bulletin,2016,(07):697.[doi:10.3969/j.issn.1001-1978.2016.05.020]
[6]张 伟,俞仲毅,梅泰中,等.蒺藜皂苷抗抑郁作用及机制研究[J].中国药理学通报,2017,(03):343.[doi:10.3969/j.issn.1001-1978.2017.03.011]
 ZHANG Wei,Yu Zhong-yi,Mei Tai-zhong,et al.Antidepressant effect and mechanism of Gross saponins of Tribulus terrestris[J].Chinese Pharmacological Bulletin,2017,(07):343.[doi:10.3969/j.issn.1001-1978.2017.03.011]
[7]吴梦瑶,赵洪庆,杨 琴,等.慢性皮质酮注射诱导焦虑性抑郁树鼩模型的研究[J].中国药理学通报,2018,(01):141.[doi:10.3969/j.issn.1001-1978.2018.01.029]
 WU Meng-yao,ZHAO Hong-qing,YANG Qin,et al.Study on model of tree shrew induced by chronic corticosterone injection in anxious depression[J].Chinese Pharmacological Bulletin,2018,(07):141.[doi:10.3969/j.issn.1001-1978.2018.01.029]
[8]王 煜,李承德,曲敬蓉,等.黄芪多糖对抑郁大鼠海马NF-κB信号通路的影响[J].中国药理学通报,2018,(06):836.[doi:10.3969/j.issn.1001-1978.2018.06.019]
 WANG Yu,LI Cheng-de,QU Jing-rong,et al.Effects of astragalus polysaccharide on hippocampal NF-κB signaling in rats with depressive behaviors[J].Chinese Pharmacological Bulletin,2018,(07):836.[doi:10.3969/j.issn.1001-1978.2018.06.019]
[9]陈建新,陈 悦,姚丽华,等.氟西汀抑制慢性应激诱导的小鼠海马胃泌素释放肽受体表达增高[J].中国药理学通报,2018,(11):1566.[doi:10.3969/j.issn.1001-1978.2018.11.018]
 CHEN Jian-xin,CHEN Yue,YAO Li-hua,et al.Inhibition of fluoxetine on increased expression of gastrin-releasing peptide receptors in hippocampus of mice induced by chronic unpredictable stress[J].Chinese Pharmacological Bulletin,2018,(07):1566.[doi:10.3969/j.issn.1001-1978.2018.11.018]
[10]郑星星,刘嘉辉,刘明辉,等.欧前胡素抗抑郁作用及机制研究[J].中国药理学通报,2019,(01):101.[doi:10.3969/j.issn.1001-1978.2019.01.020]
 ZHENG Xing-xing,LIU Jia-hui,LIU Ming-hui,et al.Antidepressant effect and mechanism of imperatorin[J].Chinese Pharmacological Bulletin,2019,(07):101.[doi:10.3969/j.issn.1001-1978.2019.01.020]

备注/Memo

备注/Memo:
基金项目:国家级“十二五计划”项目课题(No 2012BAIO1B05); 国家自然科学基金项目(No 30971040,81271496)
作者简介:陈建新(1970-),男,博士,讲师,研究方向:精神药理学,E-mail:CHY_990802@163.com;
王高华(1964-),男,教授,博士生导师,研究方向:精神药理学,通讯作者,E-mail:WGH_640806@163.com
更新日期/Last Update: 2016-07-15